BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

541 related articles for article (PubMed ID: 26405092)

  • 1. A Randomized Phase II/III Study of Dalotuzumab in Combination With Cetuximab and Irinotecan in Chemorefractory, KRAS Wild-Type, Metastatic Colorectal Cancer.
    Sclafani F; Kim TY; Cunningham D; Kim TW; Tabernero J; Schmoll HJ; Roh JK; Kim SY; Park YS; Guren TK; Hawkes E; Clarke SJ; Ferry D; Frödin JE; Ayers M; Nebozhyn M; Peckitt C; Loboda A; Mauro DJ; Watkins DJ
    J Natl Cancer Inst; 2015 Dec; 107(12):djv258. PubMed ID: 26405092
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dalotuzumab in chemorefractory KRAS exon 2 mutant colorectal cancer: Results from a randomised phase II/III trial.
    Sclafani F; Kim TY; Cunningham D; Kim TW; Tabernero J; Schmoll HJ; Roh JK; Kim SY; Park YS; Guren TK; Hawkes E; Clarke SJ; Ferry D; Frodin JE; Ayers M; Nebozhyn M; Peckitt C; Loboda A; Watkins DJ
    Int J Cancer; 2017 Jan; 140(2):431-439. PubMed ID: 27681944
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer.
    Peeters M; Price TJ; Cervantes A; Sobrero AF; Ducreux M; Hotko Y; André T; Chan E; Lordick F; Punt CJ; Strickland AH; Wilson G; Ciuleanu TE; Roman L; Van Cutsem E; Tzekova V; Collins S; Oliner KS; Rong A; Gansert J
    J Clin Oncol; 2010 Nov; 28(31):4706-13. PubMed ID: 20921462
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study.
    Douillard JY; Siena S; Cassidy J; Tabernero J; Burkes R; Barugel M; Humblet Y; Bodoky G; Cunningham D; Jassem J; Rivera F; Kocákova I; Ruff P; Błasińska-Morawiec M; Šmakal M; Canon JL; Rother M; Oliner KS; Wolf M; Gansert J
    J Clin Oncol; 2010 Nov; 28(31):4697-705. PubMed ID: 20921465
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer.
    Loupakis F; Pollina L; Stasi I; Ruzzo A; Scartozzi M; Santini D; Masi G; Graziano F; Cremolini C; Rulli E; Canestrari E; Funel N; Schiavon G; Petrini I; Magnani M; Tonini G; Campani D; Floriani I; Cascinu S; Falcone A
    J Clin Oncol; 2009 Jun; 27(16):2622-9. PubMed ID: 19398573
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SPIRITT: A Randomized, Multicenter, Phase II Study of Panitumumab with FOLFIRI and Bevacizumab with FOLFIRI as Second-Line Treatment in Patients with Unresectable Wild Type KRAS Metastatic Colorectal Cancer.
    Hecht JR; Cohn A; Dakhil S; Saleh M; Piperdi B; Cline-Burkhardt M; Tian Y; Go WY
    Clin Colorectal Cancer; 2015 Jun; 14(2):72-80. PubMed ID: 25982297
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biweekly cetuximab plus irinotecan as second-line chemotherapy for patients with irinotecan-refractory and KRAS wild-type metastatic colorectal cancer according to epidermal growth factor receptor expression status.
    Kang MJ; Hong YS; Kim KP; Kim SY; Baek JY; Ryu MH; Lee JL; Chang HM; Kim MJ; Chang HJ; Kang YK; Kim TW
    Invest New Drugs; 2012 Aug; 30(4):1607-13. PubMed ID: 21706149
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of KRAS mutations in predicting the efficacy of cetuximab-plus-irinotecan therapy in irinotecan-refractory Korean metastatic colorectal cancer patients.
    Sohn BS; Kim TW; Lee JL; Ryu MH; Chang HM; Kang YK; Park HS; Na YS; Jang SJ; Kim JC; Lee JS
    Oncology; 2009; 77(3-4):224-30. PubMed ID: 19738388
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Abituzumab combined with cetuximab plus irinotecan versus cetuximab plus irinotecan alone for patients with KRAS wild-type metastatic colorectal cancer: the randomised phase I/II POSEIDON trial.
    Élez E; Kocáková I; Höhler T; Martens UM; Bokemeyer C; Van Cutsem E; Melichar B; Smakal M; Csőszi T; Topuzov E; Orlova R; Tjulandin S; Rivera F; Straub J; Bruns R; Quaratino S; Tabernero J
    Ann Oncol; 2015 Jan; 26(1):132-140. PubMed ID: 25319061
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dual targeting of the epidermal growth factor receptor using the combination of cetuximab and erlotinib: preclinical evaluation and results of the phase II DUX study in chemotherapy-refractory, advanced colorectal cancer.
    Weickhardt AJ; Price TJ; Chong G; Gebski V; Pavlakis N; Johns TG; Azad A; Skrinos E; Fluck K; Dobrovic A; Salemi R; Scott AM; Mariadason JM; Tebbutt NC
    J Clin Oncol; 2012 May; 30(13):1505-12. PubMed ID: 22412142
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TIMP-1 and CEA as biomarkers in third-line treatment with irinotecan and cetuximab for metastatic colorectal cancer.
    Spindler KL; Christensen IJ; Nielsen HJ; Jakobsen A; Brünner N
    Tumour Biol; 2015 Jun; 36(6):4301-8. PubMed ID: 25608838
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FOLFIRI and Cetuximab Every Second Week for First-Line Treatment of KRAS Wild-Type Metastatic Colorectal Cancer According to Phosphatase and Tensin Homolog Expression: A Phase II Study.
    Personeni N; Rimassa L; Verusio C; Barni S; Rubino L; Bozzarelli S; Villa E; Carnaghi C; Tronconi MC; Gerardi C; Galli F; Floriani I; Destro A; Raschioni C; Labianca R; Santoro A
    Clin Colorectal Cancer; 2015 Sep; 14(3):162-9. PubMed ID: 25861836
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of HER-3, insulin growth factor-1, nuclear factor-kB and epidermal growth factor receptor gene copy number in the prediction of clinical outcome for K-RAS wild-type colorectal cancer patients receiving irinotecan-cetuximab.
    Scartozzi M; Giampieri R; Maccaroni E; Mandolesi A; Giustini L; Silva R; Zaniboni A; Biscotti T; Biagetti S; Galizia E; Loupakis F; Falcone A; Bearzi I; Cascinu S
    Ann Oncol; 2012 Jul; 23(7):1706-12. PubMed ID: 22112971
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized, phase II study of the insulin-like growth factor-1 receptor inhibitor IMC-A12, with or without cetuximab, in patients with cetuximab- or panitumumab-refractory metastatic colorectal cancer.
    Reidy DL; Vakiani E; Fakih MG; Saif MW; Hecht JR; Goodman-Davis N; Hollywood E; Shia J; Schwartz J; Chandrawansa K; Dontabhaktuni A; Youssoufian H; Solit DB; Saltz LB
    J Clin Oncol; 2010 Sep; 28(27):4240-6. PubMed ID: 20713879
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase III randomized, placebo-controlled study of cetuximab plus brivanib alaninate versus cetuximab plus placebo in patients with metastatic, chemotherapy-refractory, wild-type K-RAS colorectal carcinoma: the NCIC Clinical Trials Group and AGITG CO.20 Trial.
    Siu LL; Shapiro JD; Jonker DJ; Karapetis CS; Zalcberg JR; Simes J; Couture F; Moore MJ; Price TJ; Siddiqui J; Nott LM; Charpentier D; Liauw W; Sawyer MB; Jefford M; Magoski NM; Haydon A; Walters I; Ringash J; Tu D; O'Callaghan CJ
    J Clin Oncol; 2013 Jul; 31(19):2477-84. PubMed ID: 23690424
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cetuximab plus irinotecan after irinotecan failure in elderly metastatic colorectal cancer patients: clinical outcome according to KRAS and BRAF mutational status.
    Fornaro L; Baldi GG; Masi G; Allegrini G; Loupakis F; Vasile E; Cupini S; Stasi I; Salvatore L; Cremolini C; Vincenzi B; Santini D; Tonini G; Graziano F; Ruzzo A; Canestrari E; Magnani M; Falcone A
    Crit Rev Oncol Hematol; 2011 Jun; 78(3):243-51. PubMed ID: 20619672
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Correlation between gene expression of IGF-1R pathway markers and cetuximab benefit in metastatic colorectal cancer.
    Huang F; Xu LA; Khambata-Ford S
    Clin Cancer Res; 2012 Feb; 18(4):1156-66. PubMed ID: 22294722
    [TBL] [Abstract][Full Text] [Related]  

  • 18. RE: A Randomized Phase II/III Study of Dalotuzumab in Combination With Cetuximab and Irinotecan in Chemorefractory, KRAS Wild-Type, Metastatic Colorectal Cancer.
    Wen-zhuo H; Liang-ping X
    J Natl Cancer Inst; 2016 Mar; 108(3):. PubMed ID: 26754849
    [No Abstract]   [Full Text] [Related]  

  • 19. Cetuximab plus capecitabine and irinotecan compared with cetuximab plus capecitabine and oxaliplatin as first-line treatment for patients with metastatic colorectal cancer: AIO KRK-0104--a randomized trial of the German AIO CRC study group.
    Moosmann N; von Weikersthal LF; Vehling-Kaiser U; Stauch M; Hass HG; Dietzfelbinger H; Oruzio D; Klein S; Zellmann K; Decker T; Schulze M; Abenhardt W; Puchtler G; Kappauf H; Mittermüller J; Haberl C; Schalhorn A; Jung A; Stintzing S; Heinemann V
    J Clin Oncol; 2011 Mar; 29(8):1050-8. PubMed ID: 21300933
    [TBL] [Abstract][Full Text] [Related]  

  • 20. EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer.
    Sobrero AF; Maurel J; Fehrenbacher L; Scheithauer W; Abubakr YA; Lutz MP; Vega-Villegas ME; Eng C; Steinhauer EU; Prausova J; Lenz HJ; Borg C; Middleton G; Kröning H; Luppi G; Kisker O; Zubel A; Langer C; Kopit J; Burris HA
    J Clin Oncol; 2008 May; 26(14):2311-9. PubMed ID: 18390971
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.